KROMATID provides proprietary platforms that detect chromosomal structural rearrangements using combined imaging and bioinformatics capabilities. The company supports gene and cell therapy developers from discovery through regulatory approval by offering high-resolution genomic integrity analysis. KROMATID plans to use new capital to expand its platforms, scale laboratory operations, and enhance automation and throughput. It will also invest in strategic hiring across scientific, operational, and customer-facing teams. Management says the funding will accelerate commercial expansion and strengthen partnerships with pharmaceutical and academic leaders in cell and gene therapy. The company is led by CEO Jim Chomas and is based in Boulder, Colo. KromaTiD develops directional Genomic Hybridization (dGH) and Pinpoint FISH platforms that deliver single‑cell, whole‑genome structural context for genomic rearrangements. Its product suite includes recently launched dGH In‑Site and dGH SCREEN for gene editing and gene therapy applications. The company offers custom assay development, preclinical research support, and operates research and GLP laboratory services. Sales and operations are reported to be rapidly accelerating with growing market adoption. KromaTiD says the technology provides structural data that other technologies cannot and is positioned to support confirmation of genomic editing in advanced therapies. The company plans to use new capital to accelerate commercialization, support ongoing product development, and increase capacity to meet growing demand. KromaTiD develops a directional Genomic Hybridization (dGHTM) platform that provides tools for understanding the success and quality of edits at the cellular level. Led by CEO Christopher Tompkins, PhD, the Longmont, Colorado company supplies products and services used by top gene editing companies to help bring advanced therapies to market. The company focuses on enabling CRISPR and other gene editing technologies. KromaTiD completed a Series A financing round; the amount raised was not disclosed. First Capital Ventures made the investment. The company intends to use the funds to advance development of its platform, expand capability and capacity, and further optimize critical artificial intelligence-based image analysis capabilities.

Total raised

$8M

Funding rounds

3

Latest round

Series C

Latest activity

Aug 2025